Citadel Advisors
RCEL icon

Citadel Advisors’s Avita Medical RCEL Stock Holding History

Citadel Advisors’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,500
Closed -$74.2K – 14008
2025
Q4 		$74.2K Buy
21,500
+2,200
+11% +$8.78K ﹤0.01% 11840
2025
Q3 		$98.6K Buy
19,300
+900
+5% +$4.7K ﹤0.01% 11859
2025
Q2 		$97.3K Sell
18,400
-7,500
-29% -$54.6K ﹤0.01% 11373
2025
Q1 		$211K Buy
25,900
+8,800
+51% +$82.2K ﹤0.01% 10345
2024
Q4 		$219K Sell
17,100
-20,800
-55% -$245K ﹤0.01% 10286
2024
Q3 		$406K Sell
37,900
-2,100
-5% -$19.7K ﹤0.01% 8698
2024
Q2 		$317K Buy
40,000
+24,600
+160% +$234K ﹤0.01% 9032
2024
Q1 		$247K Buy
15,400
+12,400
+413% +$201K ﹤0.01% 9889
2023
Q4 		$41.2K Sell
3,000
-14,800
-83% -$170K ﹤0.01% 11987
2023
Q3 		$260K Sell
17,800
-15,900
-47% -$269K ﹤0.01% 9423
2023
Q2 		$573K Buy
33,700
+16,700
+98% +$245K ﹤0.01% 7641
2023
Q1 		$237K Buy
17,000
+13,100
+336% +$139K ﹤0.01% 9860
2022
Q4 		$25.7K Sell
3,900
-7,900
-67% -$47.3K ﹤0.01% 12916
2022
Q3 		$62K Buy
+11,800
New +$72.9K ﹤0.01% 11476
2021
Q2 		– Sell
-25,000
Closed -$496K – 14285
2021
Q1 		$496K Buy
+25,000
New +$581K ﹤0.01% 9692

Other funds holding RCEL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's RCEL Position: Q1 2026 in Review

Citadel Advisors increased its Avita Medical (RCEL) stake by 27% in Q1 2026, buying an estimated $22.8K and bringing the position to 25,624 shares worth $94.8K. The position accounts for ﹤0.01% of the portfolio, ranked #12058.

Citadel Advisors first reported a position in RCEL in Q4 2019 and has held it in 19 quarters since. The position peaked at $1.52M in Q1 2023. 79 funds tracked by Wall St. Rank hold RCEL as of Q1 2026.

  • Citadel Advisors held 25,624 shares of Avita Medical worth $94.8K as of Q1 2026.
  • Citadel Advisors bought 5,434 Avita Medical shares in Q1 2026, an estimated $22.8K.
  • Avita Medical made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12058 holding.
  • Citadel Advisors first reported a position in Avita Medical in Q4 2019 and has held it in 19 quarters since.
  • Citadel Advisors's Avita Medical position peaked at $1.52M in Q1 2023.
  • 79 funds tracked by Wall St. Rank held Avita Medical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.